RECRUITING

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

Official Title

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Quick Facts

Study Start:2025-08-17
Study Completion:2031-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06964464

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥ 18 years
  2. * ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability
  3. * Current treatment with metoprolol succinate and willing to switch to carvedilol
  4. * LVEF \<50% during the past 12 months prior to consent
  1. * Unwilling or unable to follow the protocol
  2. * Treatment with any other ßB than metoprolol succinate or no ßB treatment
  3. * Known prior intolerance or contraindication to carvedilol
  4. * Systolic blood pressure \<100 mmHg
  5. * Enrollment in another clinical trial
  6. * Inability or unwilling to consent

Contacts and Locations

Study Contact

Mehmet Aktas, M.D.
CONTACT
585-275-5391
Mehmet_Aktas@URMC.Rochester.edu
Nicole Guerrero, MBA
CONTACT
0000000000
nicole.guerrero@heart.rochester.edu

Study Locations (Sites)

HonorHealth
Scottsdale, Arizona, 85258
United States
AdventHealth Redmond
Rome, Georgia, 30165
United States
AdventHealth Shawnee Mission
Shawnee Mission, Kansas, 66204
United States
Henry Ford Health System
Detroit, Michigan, 48202
United States
University of Mossouri
Columbia, Missouri, 65212
United States
Creighton University Medical Center
Omaha, Nebraska, 68124
United States
Suny Downstate
Brooklyn, New York, 11203
United States
New York-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, 11215
United States
University of Rochester Medical Center
Rochester, New York, 14642
United States
CHRISTUS Trinity Mother Frances Health System
Tyler, Texas, 75701
United States
Health University of Utah
Salt Lake City, Utah, 84112
United States
Virginia Commonwealth University
Richmond, Virginia, 23298
United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-17
Study Completion Date2031-07-01

Study Record Updates

Study Start Date2025-08-17
Study Completion Date2031-07-01

Terms related to this study

Keywords Provided by Researchers

  • arrhythmia
  • heart failure
  • ICD
  • implantable cardioverter defibrillator
  • ICD shock
  • carvedilol
  • metoprolol succinate
  • beta-blocker

Additional Relevant MeSH Terms

  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Sudden Cardiac Death
  • Ventricular Arrhythmia
  • Implantable Cardioverter Defibrillator (ICD)
  • Beta-blocker Therapy
  • Cardiomyopathy